|
|
Volumn 105, Issue 12, 2013, Pages 835-836
|
|
Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRACYCLINE;
ANTINEOPLASTIC AGENT;
CARDIOTONIC AGENT;
CHELATING AGENT;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ERBB2 PROTEIN, HUMAN;
MONOCLONAL ANTIBODY;
RAZOXANE;
TRASTUZUMAB;
TUMOR MARKER;
BREAST TUMOR;
CHEMICALLY INDUCED DISORDER;
CHEMISTRY;
DRUG EFFECT;
FEMALE;
HEART;
HEART FAILURE;
HEART STROKE VOLUME;
HUMAN;
MOLECULARLY TARGETED THERAPY;
NOTE;
ANTHRACYCLINES;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CARDIOTONIC AGENTS;
CHELATING AGENTS;
FEMALE;
HEART;
HEART FAILURE;
HUMANS;
MOLECULAR TARGETED THERAPY;
RAZOXANE;
RECEPTOR, ERBB-2;
STROKE VOLUME;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 84882988652
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djt161 Document Type: Note |
|
Times cited : (20)
|
|
References (0)
|
